Table 3.
Sphingosine 1-phosphate receptor (S1PR) drugs in clinical development in autoimmune diseases
| Drug | Mechanisms | Diseases | Phase |
|---|---|---|---|
| Fingolimod (FTY720) | S1PR 1, 3, 4, 5 modulator | RRMS | Approved |
| Siponimod (BAF312) | S1PR 1/5 agonist | RRMS | II (completed) II extension (completed) |
| SPMS | III (completed) | ||
| Ceralifimod(ONO-4641) | S1PR1/5 agonist | RRMS | II (completed) II extension (terminated) |
| Ponesimod (ACT128800) | S1PR1 agonist | RRMS | II (completed) II extension (completed) III (recruiting) |
| Psoriasis | II (completed) | ||
| Ozanimod (RPC1063) | S1PR1/5 agonist | RRMS | II/III (completed/active) III (active) |
| Ulcerative colitis | III (recruiting) III extension (recruiting) |
||
| Crohn’s disease | II (active, not recruiting) | ||
| LX3305 (LX2931) | S1PR lyase inhibitor | Rheumatoid arthritis | II (completed) |
| KRP-203 | S1PR1 agonist | Subacute cutaneous lupus erythematous | II (completed) |
| Ulcerative colitis | II (discontinued) | ||
| GSK2018682 | S1PR1 agonist | RRMS | I (completed) |
| AKP11 | S1PR1 agonist | Psoriasis | II (recruiting) |
| APD334 | S1PR1 agonist | Ulcerative colitis | II (recruiting) II extension (recruiting) |
| Amiselimod (MT-1303) | S1PR functional antagonist | RRMS | II (completed) |
| Inflammatory bowel disease | I (completed) | ||
| Crohn’s disease | II (active, not recruiting) | ||
| Plaque psoriasis | II (completed) | ||
| SLE | I (active, not recruiting) |
RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; SLE = systemic lupus erythematosus